Introduction {#s1}
============

Osteoarthritis (OA) is a degenerative joint disease that is primarily characterised by cartilage destruction. A variety of aetiological risk factors and pathophysiological processes contribute to the progressive nature of the disease. Important among potential OA-causing mechanisms are mechanical stresses, including joint instability and injury, and factors that predispose toward OA, such as ageing. These factors lead to the activation of biochemical pathways in chondrocytes that result in degradation of the extracellular matrix (ECM) by matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS).[@R1] We have previously demonstrated that hypoxia-inducible factor (HIF)-2α, encoded by *EPAS1*, triggers osteoarthritic cartilage destruction by upregulating chondrocyte expression of matrix-degrading enzymes.[@R4]

In a preliminary study, we identified *Nampt* as a HIF-2α-upregulated gene in mouse chondrocytes. *Nampt* encodes nicotinamide phosphoribosyltransferase, which functions as both an intracellular form (iNAMPT) and an extracellular form (eNAMPT). eNAMPT, also known as visfatin, acts as an adipokine, whereas the nicotinamide phosphoribosyltransferase enzymatic activity of iNAMPT regulates salvage pathways of NAD^+^ synthesis.[@R7] [@R8] eNAMPT displays pro-inflammatory functions and appears to be associated with inflammatory diseases, such as rheumatoid arthritis (RA).[@R9] [@R10] For instance, levels of eNAMPT in the synovial fluid of RA patients are positively related to disease severity.[@R11] eNAMPT regulates the expression of chemokines and cytokines in cell types involved in RA pathogenesis.[@R14] [@R15] Additionally, inhibition of iNAMPT enzymatic activity with FK866[@R16] blocks experimental RA.[@R17] [@R18] Similar to their association with RA, elevated eNAMPT levels are positively linked to OA pathogenesis.[@R19] eNAMPT in human OA chondrocytes inhibits proteoglycan synthesis and increases the expression of matrix-degrading enzymes.[@R20] [@R21] Additionally, interleukin (IL)-1β acts through overexpression of NAMPT to inhibit collagen type II (COL2A1) expression in chondrocytes.[@R22] Although these observations suggest a possible role for NAMPT in OA pathogenesis, the contribution of NAMPT in OA pathogenesis in vivo remains to be established. In this study, we investigated the role and underlying molecular mechanisms of HIF-2α-upregulated NAMPT in OA pathogenesis.

Materials and methods {#s2}
=====================

OA cartilage and experimental OA {#s2a}
--------------------------------

Human OA cartilage was sourced from individuals undergoing arthroplasty.[@R4] Male C57BL/6, STR/ort, CBA/CaCrl, *Col2a1-Nampt* transgenic (TG), *Epas1*^+/−^, *Epas1*^fl/fl^;*Col2a1-Cre* and *Il6^−/−^* mice were used for experimental OA studies. *Col2a1-Nampt* TG mice were generated using the *Col2a1* promoter and enhancer.[@R4] *Epas1*^+/−^, *Epas1*^fl/fl^ and *Col2a1-Cre* TG mice were obtained from the Jackson Laboratory. *Epas1*^fl/fl^;*Col2a1-Cre* and *Il6^−/−^* mice were described previously.[@R5] [@R6] Spontaneous OA in STR/ort[@R23] and *Nampt* TG mice was examined at 28 and 55 weeks of age, respectively. Experimental OA was induced by destabilisation of the medial meniscus (DMM) surgery. Mice were also injected intraperitoneally with FK886 (10 mg/kg) once every 3 days and sacrificed 8 weeks after DMM surgery. Experimental OA was additionally induced by intra-articular injection (once weekly for 3 weeks) of Ad-*Nampt* or Ad-*Epas1* (1×10^9^ plaque forming units) with or without FK886. Mice were sacrificed 21 days after the first intra-articular injection.[@R4] [@R24]

Histology and immunohistochemistry {#s2b}
----------------------------------

Human OA cartilage sections were stained with alcian blue. Cartilage destruction in mice was examined using safranin-O staining and scored using the OARSI grading system.[@R25] Synovitis was determined by haematoxylin staining. Detailed procedures are presented in online [supplementary materials](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) and methods.

Other materials and methods {#s2c}
---------------------------

Additional methods are described in online [supplementary materials](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) and methods. These include histology and immunohistochemistry; primary culture of articular chondrocytes; microarray analysis; adenoviruses, infection of chondrocytes and intra-articular injection of mice; ELISA; reverse transcription-PCR (RT-PCR), quantitative RT-PCR (qRT-PCR) and small inhibitory RNA; western blotting; cloning, reporter gene assays and ChIP assays; skeletal staining; and MMP activity assays. PCR primer and siRNA sequences are summarised in online supplementary Table S1 and Table S2, respectively.

Statistical analysis {#s2d}
--------------------

Values are presented as means±SEM. The n numbers indicated for each figure correspond to the number of independent experiments or the number of mice used. Data quantified based on an ordinal grading system, such as OARSI grade, were analysed using non-parametric statistical methods. For qRT-PCR, data expressed as relative fold changes, Student t test and analysis of variance with post hoc tests were used for pair-wise comparisons and multi-comparisons, respectively, after first confirming a normal distribution using the Shapiro--Wilk test. Significance was accepted at the 0.05 level of probability (p\<0.05).

Results {#s3}
=======

HIF-2α directly targets the *Nampt* gene in articular chondrocytes {#s3a}
------------------------------------------------------------------

Microarray analyses of chondrocytes infected with Ad-*Epas1* indicated upregulation of *Nampt* (visfatin) and downregulation of *Adipoq* (adiponectin), *Retn* (resistin) and *Lep* (leptin) (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S1). Differential adipokine expression was additionally confirmed in primary cultured chondrocytes ([figure 1](#ANNRHEUMDIS2013204355F1){ref-type="fig"}A). We focused on the role of NAMPT, whose corresponding gene is positively regulated by HIF-2α, in OA pathogenesis. ChIP assays revealed that HIF-2α binds to the proximal site among the three HIF-2α binding sites (CGTG) in the mouse *Nampt* promoter ([figure 1](#ANNRHEUMDIS2013204355F1){ref-type="fig"}B). HIF-2α stimulated *Nampt* promoter activity, an effect that was inhibited by co-transfection of dominant-negative (Δ) HIF-2α ([figure 1](#ANNRHEUMDIS2013204355F1){ref-type="fig"}C). Mutation of the proximal site, but not other HIF-2α binding sites, inhibited reporter gene activity ([figure 1](#ANNRHEUMDIS2013204355F1){ref-type="fig"}C). These results collectively show that the *Nampt* gene is a direct target of HIF-2α in chondrocytes.

![*Nampt* is a direct target gene of HIF-2α in mouse articular chondrocytes. (A) qRT-PCR (n=6) and western blotting of HIF-2α and NAMPT in chondrocytes infected with Ad-C (800 MOI) or Ad-*Epas1* for 24 h. (B) HIF-2α binding to the *Nampt* promoter was detected by ChIP assay in chondrocytes treated with IL-1β (1 ng/mL) or infected with Ad-*Epas1*. The *Nampt* coding sequence (CDS) was used as a negative control. IgG was used as an isotype control for the anti-HIF-2α antibody. (C) *Nampt* reporter gene activity in chondrocytes transfected with empty vector (EV), *Epas1* vector or Δ*Epas1* vector (n=6) (left). Reporter gene activity of wild-type (WT) and HIF-2α binding site-mutated reporter genes (n=6) (right). \*p\<0.01, \*\*p\<0.001.](annrheumdis-2013-204355f01){#ANNRHEUMDIS2013204355F1}

NAMPT is required for HIF-2α-induced MMP expression {#s3b}
---------------------------------------------------

We next investigated the possible role of NAMPT in the expression of matrix-degrading enzymes and ECM proteins in chondrocytes. Overexpression of NAMPT by Ad-*Nampt* infection induced upregulation and activation of the MMP3, MMP12 and MMP13, and downregulation of aggrecan without significant effects on COL2A1 expression ([figure 2](#ANNRHEUMDIS2013204355F2){ref-type="fig"}A,B and online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S2A). ELISAs revealed that both iNAMPT and eNAMPT were produced by Ad-*Nampt* infection ([figure 2](#ANNRHEUMDIS2013204355F2){ref-type="fig"}C). The significance of NAMPT enzymatic activity was determined using the specific inhibitor FK866.[@R16] FK866 significantly blocked Ad-*Nampt*-induced upregulation of MMP, MMP12 and MMP13 ([figure 2](#ANNRHEUMDIS2013204355F2){ref-type="fig"}D and online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S2B). eNAMPT action was assessed by treating chondrocytes with recombinant mouse NAMPT protein (rNAMPT). rNAMPT stimulated the expression of MMPs (MMP3, MMP12 and MMP13) and downregulated aggrecan ([figure 2](#ANNRHEUMDIS2013204355F2){ref-type="fig"}E and online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S2C). However, addition of a neutralising antibody against eNAMPT did not affect Ad-*Nampt*-induced upregulation of MMP3, MMP12 and MMP13 (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S2D). Additionally, HIF-2α-induced MMP expression was significantly blocked by knockdown or inhibition of NAMPT ([figure 2](#ANNRHEUMDIS2013204355F2){ref-type="fig"}F and online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S2E). NAMPT overexpression in chondrocytes also upregulated various cytokines and chemokines (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S3). Among these, IL-6 induced upregulation of MMP3 and MMP13, consistent with a previous report.[@R6] Experiments using chondrocytes from *Il6*^−/−^ mice demonstrated that NAMPT-induced MMP3 expression was at least partly mediated by IL-6 production (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S3). However, treatment of Ad-*Epas1*-infected chondrocytes with other adipokines (ie, resistin, adiponectin and leptin) did not affect HIF-2α-induced upregulation of MMPs (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S4). Collectively, these results indicate that NAMPT promotes upregulation of MMP3, MMP12 and MMP13 in chondrocytes, an action that is necessary for HIF-2α-induced expression of catabolic enzymes.

![NAMPT is required for HIF-2α-induced matrix metalloproteinase (MMP) expression in chondrocytes. (A) Detection of the indicated mRNAs/proteins by qRT-PCR/western blotting in chondrocytes infected with Ad-C or Ad-*Nampt* (n=6). (B) MMP activity assays in chondrocytes infected with Ad-C (800 MOI) or Ad-*Nampt* (n=5). (C) NAMPT levels quantified by ELISA (n=5) in chondrocytes infected with Ad-C (800 MOI) or Ad-*Nampt*. (D) Expression levels of catabolic factors determined by qRT-PCR (n=6) in chondrocytes infected at an MOI of 800 with Ad-C or Ad-*Nampt* in the absence or presence of FK866 (100 μM). (E) qRT-PCR (n=6) in chondrocytes treated with recombinant NAMPT (rNAMPT). (F) Chondrocytes were transfected with 100 nM control siRNA (C-siRNA) or *Nampt* siRNA, or were treated with or without FK866 (100 μM) and exposed to Ad-*Epas1* for 36 h. mRNA levels were determined by qRT-PCR (n=6). \*p\<0.01, \*\*p\<0.001.](annrheumdis-2013-204355f02){#ANNRHEUMDIS2013204355F2}

NAMPT is upregulated in OA cartilage {#s3c}
------------------------------------

To ascertain whether NAMPT plays a role in OA pathogenesis, we examined NAMPT expression in OA cartilage of humans and mice. NAMPT mRNA and protein were markedly elevated in OA-affected human cartilage compared with undamaged regions of arthritic cartilage ([figure 3](#ANNRHEUMDIS2013204355F3){ref-type="fig"}A). NAMPT levels were also increased in mouse OA models, including STR/ort mouse OA cartilage ([figure 3](#ANNRHEUMDIS2013204355F3){ref-type="fig"}B) and OA cartilage induced by DMM surgery ([figure 3](#ANNRHEUMDIS2013204355F3){ref-type="fig"}C). OA cartilage in both humans and mouse models shows increased expression of HIF-2α.[@R4] Consistent with this, overexpression of HIF-2α in articular cartilage by intra-articular injection of Ad-*Epas1* increased NAMPT levels, with concomitant osteoarthritic cartilage destruction ([figure 4](#ANNRHEUMDIS2013204355F4){ref-type="fig"}A). Additionally, DMM-induced NAMPT upregulation and OA cartilage destruction were significantly blocked in chondrocyte-specific *Epas1* conditional knockout (CKO) mice ([figure 4](#ANNRHEUMDIS2013204355F4){ref-type="fig"}B,C), indicating that NAMPT expression in chondrocytes of OA cartilage is regulated by HIF-2α.

![NAMPT is overexpressed in human and mouse osteoarthritis (OA) chondrocytes. (A) Alcian blue staining, NAMPT immunostaining and NAMPT mRNA levels quantified by qRT-PCR of human OA cartilage. (B and C) Spontaneous OA cartilage from STR/ort mice and CBA control mice (B), and sham- and destabilisation of the medial meniscus (DMM)-operated C57BL/6 mice (C). mRNA levels in cartilage tissue were quantified by qRT-PCR (n=10). \*\*p\<0.001. Scale bar: 50 μm.](annrheumdis-2013-204355f03){#ANNRHEUMDIS2013204355F3}

![NAMPT expression in osteoarthritis cartilage is regulated by HIF-2α. (A) Cartilage tissue of mice, intra-articularly injected with Ad-C or Ad-*Epas1*, was used for safranin-O staining, OARSI grade, and immunodetection/qRT-PCR of HIF-2α and NAMPT proteins/mRNAs (n=6). (B and C) Safranin-O staining, immunostaining for HIF-2α and NAMPT, OARSI grade, and qRT-PCR of NAMPT and HIF-2α mRNAs (n=10) in wild-type (WT) and *Epas1* conditional knockout (CKO) mice following destabilisation of the medial meniscus (DMM) surgery. \*p\<0.001. Scale bar: 100 μm.](annrheumdis-2013-204355f04){#ANNRHEUMDIS2013204355F4}

NAMPT causes experimental OA cartilage destruction {#s3d}
--------------------------------------------------

The role of NAMPT in OA pathogenesis in mice was examined by intra-articular injection of Ad-*Nampt*, which caused NAMPT overexpression in cartilage, meniscus and synovium ([figure 5](#ANNRHEUMDIS2013204355F5){ref-type="fig"}A and online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S5A). Gene delivery by intra-articular injection of adenovirus was further confirmed by monitoring injected Ad-*Gfp* (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S5B). Ad-*Nampt* injection triggered cartilage destruction with significantly increased expression of the NAMPT targets MMP3, MMP12 and MMP13 in cartilage tissue ([figures 5](#ANNRHEUMDIS2013204355F5){ref-type="fig"}A,B). Ad-*Nampt* injection additionally resulted in synovitis (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S5C). The role of NAMPT was further validated by generating *Col2a1-Nampt* TG mice. Chondrocytes from these mice, which showed no developmental defects (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S6), exhibited elevated mRNA levels of NAMPT and its target genes compared with wild-type (WT) chondrocytes ([figure 5](#ANNRHEUMDIS2013204355F5){ref-type="fig"}C). Consistent with this, *Col2a1-Nampt* TG mice showed significantly enhanced osteoarthritic cartilage destruction following DMM surgery ([figure 5](#ANNRHEUMDIS2013204355F5){ref-type="fig"}D). Moreover, aged (12-month-old) TG mice showed spontaneous cartilage destruction compared with WT mice of the same age ([figure 5](#ANNRHEUMDIS2013204355F5){ref-type="fig"}E). Thus, gain-of-function studies of NAMPT collectively indicate that NAMPT is an important catabolic regulator of OA pathogenesis.

![Overexpression of NAMPT in chondrocytes causes osteoarthritis cartilage destruction. (A and B) Mice were Intra-articularly injected with Ad-C or Ad-*Nampt* and evaluated by (A) NAMPT immunostaining, safranin-O staining and OARSI grading (n=6), and (B) qRT-PCR (n=6) of catabolic factors in cartilage tissues. (C) qRT-PCR of mRNAs in chondrocytes isolated from wild-type (WT) or *Col2a1*-*Nampt* transgenic (TG) mice (n=7). (D) NAMPT immunostaining, safranin-O staining and OARSI grade (n=13) in destabilisation of the medial meniscus (DMM)- or sham-operated WT and *Col2a1*-*Nampt* TG mice. (E) Spontaneous cartilage destruction in 12-month-old WT and TG mice determined by safranin-O staining and OARSI grade (n=10). \*p\<0.01, \*\*p\<0.001. Scale bar: 100 μm.](annrheumdis-2013-204355f05){#ANNRHEUMDIS2013204355F5}

NAMPT is required for experimental OA cartilage destruction {#s3e}
-----------------------------------------------------------

Because iNAMPT enzymatic activity is necessary for MMP expression, we examined whether iNAMPT regulates OA pathogenesis. Injection of FK866 (intraperitoneally or intra-articularly) significantly inhibited cartilage destruction induced by Ad-*Nampt* injection ([figure 6](#ANNRHEUMDIS2013204355F6){ref-type="fig"}A), with concomitant reduction of the mRNA levels NAMPT targets MMP3, MMP12 and MMP13 in cartilage tissue (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S7A). Intraperitoneal injection of FK866 also inhibited DMM-induced cartilage destruction ([figure 6](#ANNRHEUMDIS2013204355F6){ref-type="fig"}B) and upregulation of NAMPT target MMPs (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S7B). Finally, injection of FK866 (intraperitoneally or intra-articularly) blocked Ad-*Epas1*-induced cartilage destruction and expression of NAMPT target MMPs ([figure 6](#ANNRHEUMDIS2013204355F6){ref-type="fig"}C and online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S7C). Additionally, synovitis caused by Ad-*Epas1* or Ad-*Nampt* injection was blocked by co-injection of FK866 (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S8). However, knockdown of *Epas1* in *Epas1*^+/−^ or *Epas1*^fl/fl^;*Col2a1-Cre* mice did not affect the cartilage destruction induced by Ad-*Nampt* injection (online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-204355/-/DC1) S9), suggesting that NAMPT is downstream of HIF-2α. These results collectively indicate that iNAMPT enzymatic activity is necessary for OA pathogenesis induced by DMM surgery or intra-articular injection of Ad-*Nampt* or Ad-*Epas1*.

![Inhibition of NAMPT enzymatic activity blocks osteoarthritis cartilage destruction. (A) Mice were intra-articularly injected with Ad-C or Ad-*Nampt* and co-injected (intra-articularly or intraperitoneally) with FK866. Cartilage destruction was detected by safranin-O staining and quantified by OARSI grade (n=10). (B) Mice were intraperitoneally injected with FK866 after destabilisation of the medial meniscus (DMM) surgery. Cartilage destruction was detected and quantified (n=10). (C) Mice were intra-articularly injected with Ad-C or Ad-*Epas1* and co-injected (intra-articularly or intraperitoneally) with FK866. Cartilage destruction was detected and quantified (n=10). \*\*p\<0.001. Scale bar: 100 μm.](annrheumdis-2013-204355f06){#ANNRHEUMDIS2013204355F6}

Discussion {#s4}
==========

Catabolic signals in OA pathogenesis are categorised into two main pathways: upregulation of tissue-destructive enzymes such as MMP3, MMP13 and ADAMTS5, and downregulation of cartilage-specific ECM proteins such as type II collagen and aggrecan. HIF-2α serves as an essential catabolic regulator of OA pathogenesis by upregulating tissue-destructive genes.[@R4] We demonstrated here that NAMPT, whose corresponding gene is a direct target of HIF-2α, plays an essential role in OA pathogenesis by upregulating matrix-degrading enzymes and downregulating aggrecan expression. Our gain-of-function studies (intra-articular injection of Ad-*Nampt*; *Col2a1-Nampt* TG mice) and loss-of-function studies (intra-articular injection of FK866) demonstrated that NAMPT is an essential catabolic regulator of OA pathogenesis. NAMPT appears to exert its catabolic functions by downregulating aggrecan and upregulating MMP3 and MMP13, which are critical effectors of OA pathogenesis.[@R26] [@R27] The mechanism by which NAMPT regulates MMP expression was not elucidated in this study. However, because NAMPT acts as an enzyme and adipokine, we speculate that NAMPT regulates the expression of MMP genes indirectly, rather than by directly modulating the activity of their promoters. Possible mechanisms include modulation of chromatin functions by NAMPT-regulated members of the Sirtuin family[@R7] [@R28] and regulation by secondary mediators such as cytokines and chemokines that are upregulated by NAMPT. Indeed, we found that NAMPT-induced MMP3 expression is mediated, at least in part, by IL-6. In addition to the NAMPT target MMPs, MMP9 was also upregulated in OA cartilage induced in response to DMM surgery or Ad-*Epas1* injection, and intra-articular injection of FK866 inhibited both cartilage destruction and MMP9 expression. Because NAMPT does not directly modulate MMP9 expression, we speculate that the inhibitory effect of FK866 on MMP9 expression is attributable to inhibition of osteoarthritic cartilage destruction by FK866.

Our results suggest that iNAMPT enzymatic activity plays an important role in the regulation of catabolic factor expression and is sufficient to promote OA pathogenesis. Consistent with this, administration of FK866 abolished experimental OA induced by DMM surgery or injection of Ad-*Nampt* or Ad-*Epas1*. However, eNAMPT also appears to plays a role in OA pathogenesis. This is clearly demonstrated by the observations that Ad-*Nampt* or Ad-*Epas1* infection increased both iNAMPT and eNAMPT and that rNAMPT treatment caused upregulation of MMP3, MMP12 and MMP13. To date, the contribution of NAMPT to OA pathogenesis has not been established *in vivo*, although *in vitro* studies have suggested possible functions in OA pathogenesis.[@R19] Therefore, our results are the first evidence for in vivo catabolic functions of NAMPT in the pathogenesis of OA. Intra-articular injection of Ad-*Nampt* also caused synovitis, which was blocked by inhibition of NAMPT enzymatic activity. Because OA is a disease that involves all joint tissues, including cartilage, synovium and subchondral bone, the synovial inflammation may affect cartilage destruction; hence, the inhibitory effects of the NAMPT inhibitor FK866 on synovitis may contribute to the observed effects on cartilage destruction.

NAMPT enzymatic activity regulates salvage pathways of NAD^+^ synthesis,[@R7] [@R8] and NAD^+^, in turn, is an essential cofactor of Sirtuin (SIRT) family protein deacetylases.[@R7] [@R29] Indeed, we found that NAMPT and HIF-2α increased NAD^+^ levels and SIRT1 activity in chondrocytes (data not shown). Among Sirtuin family members, SIRT1 is known to deacetylate HIF-2α,[@R30] [@R31] whereas SIRT7 negatively regulates HIF-2α protein stability.[@R32] Evidence suggests a possible function of SIRT1 in OA pathogenesis through the regulation of cartilage ECM expression and chondrocyte apoptosis.[@R33] [@R34] Additionally, *Sirt1*-CKO mice or *Sirt1* mutant mice exhibit enhanced osteoarthritic cartilage destruction,[@R34] [@R35] suggesting that SIRT1 plays a cartilage-protective role. This is a somewhat contradictory finding given the pro-inflammatory and catabolic functions of its upstream activator NAMPT. However, we found that SIRT activity is required for protein stability and transcriptional activity of HIF-2α, and thereby regulates the induction of matrix-degrading enzymes and OA pathogenesis in various mouse models (data not shown). This suggests that other member(s) of the Sirtuin family, rather than SIRT1, is associated with HIF-2α/NAMPT regulation of OA pathogenesis.

In summary, we found that *Nampt* is a direct target gene of HIF-2α in articular chondrocytes and is upregulated in OA cartilage. We also demonstrated by gain-of-function/loss-of-function studies that NAMPT plays an essential catabolic role in OA pathogenesis and acts as a crucial mediator of osteoarthritic cartilage destruction caused by HIF-2α or DMM surgery. Therefore, NAMPT could be an effective therapeutic target in the treatment of OA disease. Indeed, inhibition of NAMPT enzymatic activity by injection of FK866 (intra-articularly or intraperitoneally) inhibits osteoarthritic cartilage destruction caused by DMM surgery or intra-articular injection of Ad-*Epas1* or Ad-*Nampt*.
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